n-methyl-3,4-methylenedioxyamphetamine has been researched along with Anxiety Neuroses in 16 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This infrequent dosing mitigates adverse event frequency and improves the risk/benefit ratio of MDMA, which may provide a significant advantage over medications that require daily dosing." | 2.82 | MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. ( Danforth, AL; Grob, CS; Struble, CM; Yazar-Klosinski, B, 2016) |
| " Problematic ecstasy users reported significantly higher levels of ecstasy use, including lifetime consumption, average dosage and binge consumption compared to non-problematic ecstasy users." | 1.33 | Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors. ( Parrott, AC; Soar, K; Turner, JJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Kisely, S | 1 |
| Connor, M | 1 |
| Somogyi, AA | 1 |
| Siskind, D | 1 |
| Kaplan, K | 1 |
| Kurtz, F | 1 |
| Serafini, K | 1 |
| Hanck, L | 1 |
| Schellekens, AF | 1 |
| Danforth, AL | 1 |
| Struble, CM | 1 |
| Yazar-Klosinski, B | 1 |
| Grob, CS | 1 |
| Sessa, B | 1 |
| Johansen, PØ | 1 |
| Krebs, TS | 1 |
| Fogger, SA | 1 |
| Tellier, PP | 1 |
| Arnold, DH | 1 |
| Milani, RM | 1 |
| Parrott, AC | 2 |
| Turner, JJ | 2 |
| Fox, HC | 1 |
| Thomasius, R | 1 |
| Petersen, KU | 1 |
| Zapletalova, P | 1 |
| Wartberg, L | 1 |
| Zeichner, D | 1 |
| Schmoldt, A | 1 |
| Huizink, AC | 1 |
| Ferdinand, RF | 1 |
| van der Ende, J | 1 |
| Verhulst, FC | 1 |
| Soar, K | 1 |
| Poikolainen, K | 1 |
| McCann, UD | 2 |
| Ricaurte, GA | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Placebo-controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults[NCT02008396] | Phase 2 | 12 participants (Actual) | Interventional | 2014-04-11 | Completed | ||
| Social Anxiety MDMA-Assisted Therapy Investigation (SAMATI): A Randomized, Delayed Treatment Control Phase 2 Study of the Safety and Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Social Anxiety Disorder[NCT05138068] | Phase 2 | 90 participants (Actual) | Interventional | 2022-04-13 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms. (NCT02008396)
Timeframe: Baseline to 1-Month Post Experimental Session 2
| Intervention | score on a scale (Mean) |
|---|---|
| Inactive Placebo With Psychotherapy | -19.3 |
| 75 mg to 125 mg MDMA With Psychotherapy | -44.1 |
The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms. (NCT02008396)
Timeframe: 1-Month Post Experimental Session 2
| Intervention | score on a scale (Mean) |
|---|---|
| Inactive Placebo With Psychotherapy | 64.0 |
| 75 mg to 125 mg MDMA With Psychotherapy | 46.4 |
The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms. (NCT02008396)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Inactive Placebo With Psychotherapy | 83.3 |
| 75 mg to 125 mg MDMA With Psychotherapy | 91.8 |
2 reviews available for n-methyl-3,4-methylenedioxyamphetamine and Anxiety Neuroses
| Article | Year |
|---|---|
A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders.
Topics: Adult; Anxiety Disorders; Child; Cognitive Behavioral Therapy; Developmental Disabilities; Humans; N | 2023 |
Club drugs: is it all ecstasy?
Topics: Adolescent; Adolescent Behavior; Anxiety Disorders; Humans; Illicit Drugs; Ketamine; Methamphetamine | 2002 |
1 trial available for n-methyl-3,4-methylenedioxyamphetamine and Anxiety Neuroses
| Article | Year |
|---|---|
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.
Topics: Adult; Anxiety Disorders; Autistic Disorder; Double-Blind Method; Follow-Up Studies; Humans; N-Methy | 2016 |
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.
Topics: Adult; Anxiety Disorders; Autistic Disorder; Double-Blind Method; Follow-Up Studies; Humans; N-Methy | 2016 |
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.
Topics: Adult; Anxiety Disorders; Autistic Disorder; Double-Blind Method; Follow-Up Studies; Humans; N-Methy | 2016 |
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.
Topics: Adult; Anxiety Disorders; Autistic Disorder; Double-Blind Method; Follow-Up Studies; Humans; N-Methy | 2016 |
13 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Anxiety Neuroses
| Article | Year |
|---|---|
Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report.
Topics: Adult; Anxiety Disorders; Behavior Therapy; Hallucinogens; Humans; Male; N-Methyl-3,4-methylenedioxy | 2018 |
[Hallucinogen persisting perception disorder after ecstasy use].
Topics: Anxiety Disorders; Citalopram; Depressive Disorder; Hallucinations; Hallucinogens; Humans; Male; N-M | 2013 |
Turn on and tune in to evidence-based psychedelic research.
Topics: Anxiety Disorders; Biomedical Research; Chemotherapy, Adjuvant; Hallucinogens; Humans; Lysergic Acid | 2015 |
How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale.
Topics: Anxiety Disorders; Avoidance Learning; Brain; Empathy; Fear; Humans; N-Methyl-3,4-methylenedioxyamph | 2009 |
Update on ecstasy.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Amphetamine-Related Disorders; Anxiety Disorders; Cognitio | 2011 |
Consultation with the specialist: the central serotonin syndrome: paradigm for psychotherapeutic misadventure.
Topics: Adolescent; Amphetamine-Related Disorders; Antidepressive Agents; Antitussive Agents; Anxiety Disord | 2002 |
Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users.
Topics: Adult; Amphetamine-Related Disorders; Analysis of Variance; Anxiety Disorders; Depressive Disorder; | 2004 |
Mental disorders in current and former heavy ecstasy (MDMA) users.
Topics: Adult; Amphetamine-Related Disorders; Anxiety Disorders; Cognition Disorders; Cross-Sectional Studie | 2005 |
Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study.
Topics: Adolescent; Adult; Anxiety Disorders; Child; Child, Preschool; Depressive Disorder; Female; Hallucin | 2006 |
Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Anxiety Disorders; Comorbidity; Depressive Disorde | 2006 |
Ecstasy and the antecedents of illicit drug use.
Topics: Anxiety Disorders; Depressive Disorder; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamin | 2006 |
MDMA ("ecstasy") and panic disorder: induction by a single dose.
Topics: 3,4-Methylenedioxyamphetamine; Administration, Oral; Adult; Alprazolam; Anxiety Disorders; Arousal; | 1992 |
Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Anxiety Disorders; Depressive Disorder; Female; Fo | 1991 |